Suven Life Sciences secures product patents in Australia, Eurasia and Europe
Products are being developed for cognitive disorders with high unmet medical need and with huge market potential globally
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Lupin submits NDA for Etanercept biosimilar in Japan
Etanercept (YLB113) is indicated for moderate to severe Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis
AstraZeneca sells Seroquel rights to Luye Pharma for $538 mn
It is used for the treatment of schizophrenia and bipolar disease
iPHEX 2018 begins in New Delhi
CDSCO announces one year extension of WHO-GMP certifications
Takeda to buy Shire in a $62 billion deal
It will be the largest overseas acquisition by a Japanese company
Pharma exports show sharp turnaround; cross $17 billion
After remaining in the negative territory for the first five months of the financial year 2017-18, pharma exports have picked up…
Research team uncovers mechanism of action for pore-forming bacterial toxins
The findings could help combat associated diseases and advance crop protection
Lupin gets USFDA nod for skin treatment drug
The product is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses
Suven’s facility completes USFDA inspection
The facility near Hyderabad underwent inspection from February 5-18, 2018
Marksans Pharma arm recalls Ibuprofen tablets from US
According to the US FDA, the nationwide, voluntary and ongoing recall is a Class II recall